JB Chemicals & Pharmaceuticals Limited — Q4 FY25 earnings call

Call held 15 May 2025

Management summary

J B Chemicals delivered a strong Q4 FY25, characterized by consistent outperformance in the domestic chronic segment and a recovery in the CDMO business. The company is successfully transitioning its international mix toward higher-margin private markets and CDMO projects. Management's decision to raise EBITDA margin guidance to 27-29% reflects high confidence in operating leverage and the upcoming margin-accretive transition of the ophthalmology portfolio.

Highlights

  • Revenue for Q4 FY25 grew 10% YoY to ₹949 crore; full-year FY25 revenue reached ₹3,918 crore (up 12%)

  • Operating EBITDA expanded 15% YoY to ₹240 crore, with margins improving 90 bps to 25.3%

  • Net Profit for the quarter increased 15% to ₹146 crore; full-year PAT rose 19% to ₹660 crore

  • Domestic business outpaced the Indian Pharma Market (IPM) with 13% growth vs 7% industry growth

  • CDMO segment grew 18% in Q4 to ₹129 crore, with a target run rate of ₹150 crore per quarter

  • Management raised operating EBITDA margin guidance for the third consecutive year to a range of 27-29%

  • Board recommended a final dividend of ₹7 per share, taking the total FY25 dividend to ₹15.50 per share

  • Net cash position strengthened significantly to ₹689 crore as of March 31, 2025

Key financials

  1. Revenue ₹949 Cr +10%YoY
  2. Operating EBITDA ₹240 Cr +15%YoY
  3. EBITDA Margin 25.3%
  4. Net Profit ₹146 Cr +15%YoY
  5. Gross Margin 66.1%
  6. Earnings Per Share —

What they filed

Q4 FY26: revenue down 7.2%, net profit down 35.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue952 956 914 901 1,040 +9%1,023 +7%991 +8%836 −7%
EBITDA273 268 245 231 293 +7%298 +11%270 +10%195 −16%
Net profit173 173 156 150 198 +14%200 +16%179 +15%97 −35%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹1,078 Cr Total
  • Domestic Business ₹519 Cr 48.1%
  • International Operations ₹430 Cr 39.9%
  • CDMO ₹129 Cr 12.0%

Guidance & targets

Margin

  • Operating EBITDA Margin Margin · FY26 · High confidence 27-29%

    Previously 25-27% → 27-29%

    EBITDA margins will be in the range of 27% to 29%. Once again, I will repeat, we are revising our operating EBITDA guidance for the third year in row.

    — Nikhil Chopra, CEO

Revenue

  • CDMO Quarterly Run Rate Revenue · FY26 · High confidence ₹150 crore

    Previously ₹110 crore → ₹150 crore

    our run rate that we assume with all these businesses is seeing the daylight which today is around INR110 crore every quarter should be around INR150 crore every quarter.

    — Nikhil Chopra, CEO

  • Ophthalmology Annualized Run Rate Revenue · FY27 · Medium confidence ₹230 crore

    From ₹200 crore today

    We are looking at close to INR230 crore annualized run rate franchisee when the perpetual license triggers in.

    — Kunal Khanna, President Operations

Capex

  • Annual Capex Capex · next 2 years · High confidence ₹100 crore
    Around INR100 crore over next two years, each year we continue to spend.

    — Narayan Saraf, CFO

Other

  • ESOP Expenses Other · FY26 · Medium confidence ₹41-46 crore

    From ₹55 crore today

    the ESOP number in FY26 should be in the range of around INR41 crore to INR46 crore and FY27 would be INR26 crore.

    — Narayan Saraf, CFO

Risks & concerns

  • Regulatory monitoring of Rantac

    medium

    Government has instructed manufacturers to closely monitor quality; management remains confident in its safety profile.

    Both acknowledged

  • Decline in third-party API sales

    low

    Third-party sales of diclofenac are in a mature/declining phase; company is pivoting to captive consumption for US ANDAs.

    Analyst downplayed

  • Red Sea logistics issues

    low

    Management noted trends are consistent with no significant deviation in international freight costs currently.

    Management acknowledged

Areas of evasion (2)

  • Promoter stake sale timeline
  • Specific profitability of individual business units

Q&A highlights

2 direct, 1 evasive
Regulatory risk regarding Rantac (Ranitidine) Direct
So there is no ban on the product, Rantac continues to be made available to the patients given its very strong clinical efficacy and safety profile.

Rantac is a major brand; management clarified that while quality monitoring is increased, there is no ban, mitigating a significant regulatory concern.

Asked by Tausif, BNP Paribas

Ophthalmology portfolio transition and margin impact Direct
In December 2026, the perpetual license gets triggered and we are full-fledged custodians of these trademarks... it will be significantly EBITDA-accretive.

The transition from in-licensed to owned trademarks in Dec 2026 will shift gross margins from ~20% to company averages (~66%), driving future profitability.

Asked by Gaurav, Antique Stockbroking

Potential sale of stake by promoters Evasive
It is very difficult for us to answer that question in this conference call... if it is promoter sale, in terms of what actions they want to do; we basically are at the top management where we are more focused on the business operations.

Management deflected questions regarding promoter exits, leaving uncertainty about potential changes in the company's shareholding structure.

Asked by Meghna Agarwal, Mount Intra Finance

2 min read 5 chapters

Detailed narrative

Domestic Chronic Portfolio Drives Outperformance

J B Chemicals' domestic business grew 13% in Q4 FY25, significantly outpacing the IPM's 7% growth. The chronic portfolio was the primary driver, growing at 16% YoY, led by flagship brands like Cilacar (up 19%) and Cilacar T (up 37%). The company now covers 3.5 lakh doctors and has improved field force productivity to ₹8 lakh PCPM from ₹4.6 lakh in FY21.

CDMO Segment Poised for Step-Jump in Revenue

The CDMO business reported 18% growth in Q4 with revenue of ₹129 crore. Management expects the quarterly run rate to increase from the current ₹110 crore to ₹150 crore by FY26. This growth is underpinned by new projects in lozenges, throat sprays, and iodine-based formulations for the US and European markets.

Ophthalmology Portfolio: A Margin Catalyst for FY27

The acquired ophthalmology portfolio is currently operating at a quarterly run rate of ₹48 crore with gross margins around 20%. A critical value-unlocking event is scheduled for December 2026, when the perpetual license triggers. This will transition the portfolio to owned trademarks, shifting gross margins toward the company average of ~66% and significantly boosting overall EBITDA.

International Business Mix Optimization

The company is successfully restructuring its international operations, particularly in South Africa, where it shifted from a tender-heavy model to a 65-70% private market mix. This move, while involving a ₹120 crore revenue cut in low-margin tenders, has substantially improved segment profitability. Russia remains a strong contributor with double-digit growth in branded generics.

Robust Cash Generation and Dividend Payout

JB Pharma reported one of the highest operating cash flow to EBITDA metrics in the industry at 83%, with FY25 operating cash flows reaching ₹903 crore. This strong cash generation supported a total dividend payout of ₹15.50 for the year and left the company with a net cash surplus of ₹689 crore, providing significant headroom for future inorganic acquisitions.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls